ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb’s iPREDICT Phase IIb Study

Los Angeles, California, USA, June 8th, 2022 – ImaginAb Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce that Roche has agreed to provide US approved atezolizumab (Tecentriq®)1, to Non-Small Cell Lung Cancer (NSCLC) patients who are enrolled in ImaginAb’s new Phase IIb iPREDICT study.

Read more…